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Abstract 
 
Tumor immunotherapy has come to the fore fuelled by impressive clinical responses 
to checkpoint inhibitor antibodies in a range of adult malignancies, and by the success 
of CAR T cells targeting adult and pediatric B cell malignancies. Clearly, if appropriately 
fine-tuned, the immune system has the capability to seek out and destroy cancer. 
Studies in pediatric solid cancers have not so far shown the therapeutic potential 
checkpoint inhibitors described in adults cancers and this may reflect fewer tumor 
associated antigens or different immune evasion mechanisms. One potential approach 
to overcome these limitations will be combine interventions to undermine immune 
evasion mechanisms with engineered T cell adoptive transfer.  
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The concept that the immune system can be used to recognize and destroy cancers 
is not new. In the early 20th century new York surgeon William Coley (1862-1936) 
inspired by his observation of cancer regression in patients recovering from 
septicaemia, injected cancer patients with live and then dead bacteria. Occasional 
responses are documented in his records although it is hard now to discern real cancer 
responses that could be attributed to immune activation. Nonetheless, the concept of 
cancer immunotherapy was born, and with it the belief that cancer might be inherently 
foreign to the host and hence amenable of detection and elimination. The degree of 
general acceptance of this belief has varied over the years but those who have kept 
the faith and made continuing scientific contributions to the field are to be credited for 
the resurgence of the field in the last 10 years. In 2013 Science hailed cancer 
immunotherapy as “breakthrough of the year”. What has led to this exponential 
increase in scientific and clinical trial activity in the field? There are three main areas 
of scientific and clinical observation that taken together have led to the realization that 
we have at our disposal new insights and new tools to effect dramatic  clinical 
responses in cancer patients. These are 1) increased understanding of the nature of 
immune evasion; 2) clinical breakthrough from interventions to overcome 
immunological checkpoints and 3) the blossoming of technologies for genetic 
modification of T cells into potent immune effectors. 
 
Understanding of immune evasion 
 
A prediction that follows from the theory that cancer can be seen as foreign is that 
individuals with defects of the immune system should have a higher incidence of 
cancer. For many years, the lack of experimental or observational evidence that the 
facts fitted this prediction led to widespread questioning of the underlying assumptions. 
A number of important breakthroughs have led to wholesale reappraisal. Firstly, in 
experimental animal models several groups have convincingly demonstrated that 
combining chemical carcinogenesis in combination with maneuvers to subvert the 
function of adaptive immunity leads to significant increases in the numbers of tumors 
[1].  Performing these sorts of experiments in humans is not ethically possible but 
certain experiments of nature can be observed to gain insight into human immune 
evasion. Interesting examples include the increased incidence of cancers associated 
with polymorphic variants diminishing innate immunity, higher incidence of cancer in 
the immunosuppressed, and the clinical observation of synchronous resurgence of 
cancer in multiple metastastic sites after long periods of remission. Evasion of immune 
destruction was adopted as a newly agreed hallmark of cancer in 2011 indicating the 
acceptance that it is a fundamental component of the mechanism of tumor 
development in virtually all cancers [2].  
The molecular pathways that are integral in immune evasion are also coming into 
focus. Key mechanisms include TGF-beta, JAK2-STAT3 and IDO pathways, and these 
converge to create an immunosuppressive tumor microenvironment including for 
example, high concentrations of inhibitory cytokines (IL-10, IL-17), downregulation or 
hiding of cell surface danger signals for the immune response [3], polarization of 
immune effectors toward inhibitory or regulatory pheontypes, and depletion of 
essential growth factors or amino acids for immune effector cells [4]. 
These mechanism have been shown to be common in pediatric solid cancers [5]; 
evidence including the a predominance of immunoinhibitory genes in the 
transcriptional signature associated with adverse prognosis in neuroblastoma [6], the 
activation of STAT3 and inhibitory pathways by the oncogenic PAX3-FOXO1A fusion 
protein in alveolar rhabdomyosarcoma [7], production of TGF-β by high grade glioma 
[8, 9] and the inhibitory effects of gangliosides such as GD2 in a number of childhood 
solid cancers [10]. Immune privilege is the concept that the tumor creates its own 
“immune-priviledged site; in addition to the above mentioned pathways, there is 
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evidence in many cancers for stromal cells and the tumor vasculature acting as an 
effective barrier to the passage of T cells [11]  
 
A number of trial approaches to target childhood solid tumors using immunotherapy 
have been developed. Table 1 lists representative trials and the general approaches 
are detailed below. 
 
Clinical trials targeting immunological checkpoints. 
 
The clinical responses in adult cancer patients have fed into biomarker discovery 
programmes, which are now starting to identify the predictive biomarkers of response 
and provide insights into mechanism of action of these drugs. For example in 
melanoma trials for Ipilimumab, whole exome sequencing of pre-treatment tumor 
tissue has identified mutational load and cytotoxic gene expression profile in the tumor 
environment to be correlated with clinical benefit [12]. Response rates to PD1/PD-L1 
pathway blockade similarly correlate with mutational burden and the presence of 
tumor-reactive lymphocytes; but the relationship between expression of the PD-L1 (a 
possible marker for activity of the pathway) and response is less clear; ie. correlation 
with response in some series but not others. The reason for this variation in the 
literature probably reflects the fact that some cancers appear to have deregulated PD-
L1 in tumor cells as an oncogenic event (eg secondary to genomic amplification) 
whereas in other cancers its expression is driven by a pro-inflammatory cytokine 
environment. In the latter scenario, some cancers with naturally occurring responder 
T cells might have low PD-L1 in resting state due to other mechanisms of immune 
evasion, but become PD-L1 bright following a pro-inflammatory immunotherapy, by an 
effect known as “adaptive immune resistance” in which the tumor protect itself by 
inducing PD-L1 in response to inflammatory cytokines and especially Interferon 
gamma [13]. Tumors showing adaptive immune resistance are potentially highly 
responsive to PD-L1 blockade as a component of a combination treatment. Taken 
together, a strong consensus has developed from the adult oncology field that 
response to checkpoint inhibitors as single or combination agents correlates very 
strongly with mutational burden, the presence of tumor-reactive tumor infiltrating 
lymphocytes, and a cytotoxic transcriptional signature. These three factors are closely 
related because mutational burden is directly related to neoantigen frequency. A tumor 
neoantigen is defined as a mutated amino acid sequence specific for a tumor cell, 
which can be recognized by cells of the adaptive immune system. In the case of T cells 
this occurs through the normal pathways of intracellular processing of endogenous 
proteins, which leads to peptides with high affinity for the binding pocket of MHC 
molecules to thereby be “presented” in a form that can be recognized by the T cell 
receptor. As the locations of mutations are entirely unrelated to putative MHC binding, 
whether a mutation is within a peptide fragment that happens to have sufficiently high 
affinity for self MHC-I to be displayed, is entirely a matter of chance, but the greater 
the number of tumor mutations, the greater the possibility that a neoantigen will be 
displayed [14].  
 
Childhood cancers have significantly lower mutational frequency than adult epithelial 
cancers that generally arise as a result of DNA damage due to environmental 
exposures [15]. Does this imply that there will be much lower responses to the 
checkpoint inhibitors? So far the data from trials suggest that this is the case [16].  
However there are exceptions including Hodgkin disease where response rates are 
high, possibly reflecting the presence of T cell responses against shared viral antigens 
[17], and rare childhood cancers with very high mutational burden, for example high 
grade glioma with a hyper-mutator phenotype [18]. The availablility of checkpoint 
inhibitor antibodies should also lead to a clinical trial re-evaluation of vaccine trial 
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approaches that were previously unsuccessful in pediatrics but might shown more 
effect when combined with immune-modulation.  
 
Adoptive T cell transfer and Engineering a T cell response 
 
The principle that infusion of tumor reactive T cells can effect rejection of vascularized 
solid tumors, including brain metastases was initially demonstrated using infusions of 
tumor infiltrating lymphocytes, especially in melanoma studies. Melanoma has a very 
high mutational load and the tumor antigen specificities of oligoclonal populations of 
TILs is emerging through studies utilizing next generation sequencing technologies 
[19, 20]. A vital new principle from the TIL studies is that conditioning chemotherapy 
prior to infusion of T cells greatly increases T cell proliferation and survival within the 
tumor microenvironment, as well as directly contributing to survival [21]. The 
mechanism is likely to be multifactorial and probably involves conversion of the tumor 
microenvironment from anti to pro-inflammatory, induction of immunogenic cell death, 
depletion of regulatory immune cells, and promotion of danger signals from the host 
microbiome [22]. 
Engineering of T cells provides one possible solution to the lack of naturally occurring 
T cell responses in most childhood cancers. Two broad approaches are the genetic 
modification of a T cell population with a T cell receptor (TCR) recognizing a tumor 
associated antigen (TAA), or with a Chimeric Antigen Receptor (CAR). TCR transfer 
has not been evaluated extensively in childhood solid cancer, largely because of lack 
of appropriate TAAs. CARs combine - within a single molecule - the antigen binding 
domain of a monoclonal antibody linked via a transmembrane sequence to primary 
and secondary stimulation domains that mimic potent T cells stimulation [23]. In this 
way, through transduction of a patient’s T cells with CAR, a large T cell population can 
be redirected towards a cell surface tumor associated antigen leading to potent T cell 
effector function only in the presence of the tumor [21, 24, 25]. Because the response 
is driven by antibody, it is MHC-unrestricted and can be fine-tuned for potent 
responses. Moreover, through modulation of the intracellular signalling of the CAR, 
maximal T cell responses can be optimized. The ideal T cell response will lead to 
cytotoxicity but also proliferative response and production of proinflammatory 
cytokines resulting in sustained memory responses, leading to sustained cancer 
regression.  
In the last 10 years many of the rules concerning optimal CAR T cell design have been 
learned from experience of treating patients with B cell malignancies in which CD19 
has been identified as a very effective target antigen [25-27]. It has been found that 
second generation endodomains containing CD3 zeta as well as a costimulatory 
domain are optimal; and that CD28 provides potent activation, whilst TNF superfamily 
domains such as 41BB or OX40 lead to slower but more sustained responses. It has 
been established that conditioning of the patient with chemotherapy drugs such as 
fludarabine and cyclophosphamide (Flu/Cy) greatly improved T cell engraftment, and 
that the combination is more effective that cyclophosphamide alone [28]. Hence in 
acute B cell leukaemia trials using second generation CD19 CAR T cells and 
conditioning of patients with Flu/Cy, unprecedented complete response rates of 80-
90% have been described in patients with chemotherapy-resistant disease [25].  
Encouraged by the results of the leukaemia studies, several groups have run trials 
using second generation CAR T cells in solid cancer in which equivalent 
lymphodepleting conditioning has been given. Despite good antigen expression in the 
tumor and good apparent functionality in vitro, these CAR T studies have not led to 
significant regression of solid cancers [29-31] .  
 
Inhibitory cells of the tumor microenvironment 
The term myeloid derived suppressor cells (MDSC) is used to describe cells invariably 
found both in the blood and intratumorally in cancer patients and tumor-bearing 
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animals. Several subsets in humans have been proposed, with a consensus 
phenotyping of HLA-DR negative CD33 positive cells being subdivided into MDSC of 
a more granulocytic lineage (CD15) or monocytic lineage (CD14) [32], the latter 
associated with production of  inhibitory cytokines, arginase and iNOS [33]. MDSC 
function by a number of mechanisms including depletion of the amino acids L-arginine 
and L-cysteine needed for T cell function [34, 35]. The depletion results from 
production of the enzymes arginase and inducible nitric oxide synthase-2 (iNOS2) 
consequent to local inflammatory cytokines. ARG and iNOS convert arginine to 
metabolites ornithine/urea and nitric oxide/citrulline respectively, which leads to 
downregulation of CD3-ζ component of the T cell receptor and loss of T cell function. 
MDSC also produce high concentrations of TGF-β, which polarizes T cells toward a 
regulatory phenotype (regulatory T cells, or Treg) characterized by expression of 
FOXP3 in CD4 cells. Tregs in the tumor environment in turn inhibit effector functions 
of cytotoxic and helper T cells [36-38]. COX2 expression has been documented within 
MDSC in both mouse and humans and appears to be a targetable molecule to inhibit 
MDSC function [39, 40]. Multiple lines of evidence have correlated the presence of 
MDSC with aggressive phenotype, advanced stage, resistance to immune therapies, 
and poor prognosis in many cancer types [41-43]. Other tumor infiltrating stromal cells 
may play important roles in immune evasion.  However tumor infiltrating macrophages 
(M2 macrophages), which play an important role in promoting tumor growth and 
angiogenesis, may have immune suppressive properties and can be difficult to 
distinguish from MDSCs. Several other stromal cell types have been identified as 
protecting tumors from immune attack including tumor associated fibroblasts, which 
appear to have a functional role of chemoattracting T cells to themselves and away 
from the areas of transformed cells in the tumor niche.  
 
Neuroblastoma as a model disease for strategies to overcome the inhibitory 
tumor microenvironment 
 
Neuroblastoma is a childhood tumor where some of the pathways controlling the 
mechanisms of immune evasion have been carefully worked out, providing an 
opportunity for immune targeting in combination therapies, for example with gene 
modified T cells or vaccines. A 14 gene signature derived from expression array 
analysis of neuroblastoma tumors associated with poor prognosis, which was validated 
on independent data sets, contains 5 genes reflecting the tumor microenvironment 
(CD14, CD33, IL-10, CD16, IL-6R) [6]. Collectively these genes suggest activation of 
inhibitory cytokine pathways within myeloid cells (CD14, CD33) within the tumor, for 
example activation of a STAT3-IL-6-IL-10 axis as has been described previously in 
neuroblastoma [44-46]. MDSC have been shown to be integral to neuroblastoma 
tumor growth. Neuroblastoma patients [47, 48] and tumors have heavy infiltration of 
myeloid cells [49] which produce arginase and iNOS [50] through an IL-6/STAT3 
pathway which inhibits effector T cells function and drives production of regulatory T 
cells through production of inhibitory cytokines IL-10 and TGF-β . 
 
Other lines of evidence point to multiple pathways by which neuroblastoma avoids 
immune detection. Neuroblastoma cells characteristically have very low expression of 
MHC class I [3]. They are known to secrete a number of factors to contribute to immune 
evasion; including soluble form of MICA/MICB, the receptors for the NK cell and T cell 
receptor NKG2D; these soluble forms acting as receptor antagonists [51, 52]. 
  
Approaches for Targeting Myeloid derived suppressor cells in combination 
studies with adoptive transfer of tumor-reactive T cells. 
 
MDSC have been shown to be inhibitory to the function of CAR T cells [50, 53]. Several 
therapeutic approaches have been proposed for blocking function, reducing numbers 
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of MDSC, and direct cytotoxicity. Such therapeutics could be used in combination 
treatments with adoptively transferred T cells or other immunotherapies and so could 
represent a novel approach to target mutationally quiet pediatric solid cancers (Table 
2).  
 
Blockade of MDSC function 
 
Sunitinib is a multi-target receptor tyrosine kinase inhibitor that abrogates a number of 
intracellular signaling pathways including those leading to activation of the STAT3 
transcription factor. As well as its direct anti-cancer effects, sunitinib has been shown 
to decrease function and numbers of MDSC and regulatory T cells  in cancer patients 
[43] and in preclinical models  and to be synergistic with immunotherapy [54]. Sunitinib 
has also shown synergy with tumor irradiation to decrease intratumoral MDSC number 
and function [55]. In patients treated with sunitinib there has been documented 
expansion of intratumor lymphocytes and decrease in MDSC [56] as well as decrease 
in circulating MDSC and regulatory T cells [57] 
 
Arginase production by MDSC is a central mechanism for their suppressive functions. 
Inhibitors of arginase are being developed and entering early phase evaluation in adult 
cancer patients. A number of existing drugs also inhibit arginase and other suppressive 
pathways in MDSC and could be redeployed as combination agents with 
immunotherapy. Nitroaspirin is an aspirin molecule covalently linked to nitric oxide and 
is an inhibitor of both iNOS and ARG [58]. It has an acceptable toxicity after trial in 
diabetes but there is no previous clinical trial experience in cancer. The COX-2 
pathway is known to be targetable in neuroblastoma [59, 60]. COX-2 has been 
proposed to be a mechanism of arginase expression in MDSC through production of 
prostaglandin E2 [61-64]. COX-2 inhibition can be achieved pharmacologically by a 
number of agents but the greatest experience is with celecoxib and there is emerging 
clinical data for its potential to inhibit MDSC and function in combination with 
immunotherapy [40, 62, 65-67]. Another potential inhibitor of prostaglandin signaling 
is sildenafil, which targets PDE-5 in MDSC and has been shown to augment antitumor 
immunity [68-70]. 
 
A further naturally occurring compound curcumin, which is a component of turmeric, 
has a number of biochemical properties including inhibition of COX2, which is thought 
to be mediated by inhibition of JAK2/STAT3 signaling [71, 72], and leads to 
differentiation of immature myeloid cells and enhanced immunotherapy in murine [73] 
and human [74, 75] tumor models. Curcumin, has excellent safety profile and has been 
used in pediatric cancer patients [76] but its pharmacodynamics for MDSC 
suppression has not been described. Indoleamine 2:3 dioxygenase is produced by 
MDSC as well as tumor cells and has multiple immune-inhibitory functions that appear 
to stem from tryptophan catabolism; so far however there has been limited success in 
translating IDO inhibitors into the clinic [77]. 
 
Decrease of MDSC numbers. 
 
It has been recognized that vitamin A is an essential factor of the differentiation of 
immature to mature myeloid cells [78, 79], and the use of vitamin A analogue All trans 
retinoic acid (ATRA) in acute promyelocytic leukemia mirrors this differentiation 
function. In animal studies administration of ATRA leads to decrease in MDSC 
numbers due to their differentiation into mature proinflammatory myeloid cells [80-82]. 
Indeed, use of 1μM ATRA to differentiate them into dendritic dells was one included in 
one of the early studies that defined human MDSC in cancer patients [83].  However, 
the role of ATRA on MDSC numbers has not been evaluated in human studies, and 
there are theoretical concerns regarding the ability of ATRA to induce regulatory T cells 
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[84]. The excellent safety profile and plentiful experience of ATRA in pediatric cancer 
studies make it an attractive agent to investigate in combination with adoptive T cell 
transfer.  
Another agent with intriguing MDSC differentiating properties is Polyphenon-E a 
component of green tea. Importantly, its function has been demonstrated in 
neuroblastoma models [47, 48]. However, dosages and scheduling needed for 
effective combination therapies in humans have not yet worked out. Similarly, 
withaferin A, derived from withania root extract, has anti tumor activity which is through 
to be derived from STAT3 inhibition and tumor microenvironmental effects [85, 86]. 
Studies to determine immunomodulation in clinical studies are warranted. 
A number of small molecule inhibitors and antibodies targeting the macrophage colony 
stimulating factor-1 (CSF-1) have been developed and evaluated in early phase trials. 
MDSC and tumor infiltrating macrophages express CSF-1 suggesting a potential 
combination approach with T cell transfer and other immunotherapies [87]. 
 
Cytotoxic killing of MDSC 
 
A number of approaches have been suggested for targeting these cells through their 
cytotoxic elimination or inhibition of their key functional pathways. Markers of immature 
myeloid cells such as CD33 could potentially be targeted with antibody or CAR T cells 
to decrease MDSC numbers in the tumor. Such an approach could be envisaged in 
combination with an immunotherapy targeting of a tumor antigen. Several antibodies 
or antibody/drug conjugates such as Gemtuzumab ozogamicin have been evaluated 
in AML and could potentially be investigated for their ability to kill MSDCs [88]. 
However lysis of normal myeloid cells might cause unacceptable toxicity or undermine 
functionally important cells for immunotherapy responses. Use of CAR T cells jointly 
targeting tumor antigen and myeloid antigen such as CD33 remains a possibility albeit 
with risk of toxicity through normal myeloid inhibition. Use of TRAIL targeting 
antibodies has been suggested due to the high expression of TRAIL receptor on 
MDSC [89]. 
Hitherto, clinical studies with adoptively transferred T cells have focused on the use of 
lymphodepleting agents such as fludarabine, which has limited effect on myeloid cells, 
and cyclophosphamide which has been shown to increase MDSC numbers [90-93]. 
Alternative chemotherapies which are toxic to MDSC as well as lymphodepleting, such 
as gemcitabine [94, 95] and 5-fluorouracil (5-FU) [96] could be considered as 
conditioning agents. There is contrary data on 5-FU with one study suggesting it 
increases MDSC function [97]. However there is no previous published experience of 
the use of gemcitabine for conditioning adoptive cell transfer in pediatrics and doses 
would need to be extrapolated from adult studies, for example using Gemcitabine with 
fludarabine in reduced intensity conditioning [98]. 
 
Use of checkpoint inhibitors. 
 
Antibodies blocking the PD1:PD-L1 pathway might inhibit some of the functions of 
MDSC by blocking the PD-L1 ligand, which is present on tumor infiltrating myeloid cells 
[99], and thereby preventing inhibitory signaling in the T cells via PD1. Blockade of 
CTLA-4, for example through use of Ipilimumab, might abrogate function of MDSC in 
at least 2 ways: by interfering with engagement of CTLA-4 on T cells by CD80 and 
CD86 on MDSC, and by direct cytotoxicity of regulatory T cells that are likely to be 
present in the tumor environment due to the TGF-β produced by MDSC [100]. 
Interestingly responses to ipilimumab in melanoma patients have been shown to 
correlate with decrease in circulating MDSC [101, 102]. 
 
Improve entry of T cells into tumors 
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Interference with chemokine signaling:  Evidence from adult malignancies such as 
pancreatic adenocarcinoma has identified mechanisms to concentrate lymphocytes in 
the vicinity of tumor stromal cells and prevent infiltration into the areas dense in 
malignant cells [11]. In pancreatic ductal adenocarcinoma and other tumors, tumor 
associated fibroblasts attract CXCR4 expressing T lymphocytes through upregulation 
of CXCL12, leading to a rim of T cell surrounding the tumor [103]. CXCL12 is also 
known to be a key chemokine for attracting MDSC into the tumor by a COX-2/PGE2 
mechanism [65, 104]. Disruption of the interaction with the drug Plerixafor leads to T 
cell infiltration, and its use in combination with anti-PD1 antibody leads enhances 
tumor eradication in a mouse model [103]. Neuroblastoma stromal and vascular 
structures are known to express high levels of CXCL12, with weak expression in 
neuroblasts [105] and CXCL12 homing appears to be key for neuroblastoma 
metastasis [106].  
Immunocytokines: Delivery of an inflammatory cytokine to the tumor niche through 
linkage to an antibody has the potential to achieve high functional concentrations at 
the tumor site with the avoidance of systemic toxicity [107]. One approach of interest 
in neuroblastoma is to effect local delivery of IL-2 for example by combination with the 
L19 antibody, which targets an alternatively spliced domain of fibronectin that is cancer 
specific and found in most solid tumors, and hence will localize to the extracellular 
matrix within the tumor niche.  Phase I testing in adults by repeated iv infusion reveals 
significantly less toxicity than is observed with IL-2, and with evidence of clinical activity 
in renal cell carcinoma [108]. An immunocytokine comprising humanized ch14.18 anti 
GD2 antibody fused with IL-2 also has a good safety and toxicity profile, with some 
evidence of activity in neuroblastoma and could be used to deliver local IL-2 in 
combination with GD2-CAR T cells in view of the very high target antigen density in 
this cancer [109]. 
Other approaches: A large number of other theoretical approaches to decrease MDSC 
number of functionality in the tumor environment could be considered; for example use 
of hyperbaric oxygen to decrease hypoxic drive, MEK inhibitors to inhibit pathways in 
both MDSC and tumor cells 
 
 
Concluding remarks 
 
Pediatric solid tumor oncologists should be encouraged by the successful  experience 
of immune checkpoint inhibitor antibodies in adult solid cancers, and adoptive transfer 
of tumor infiltrating lymphocytes in melanoma, or engineered T cells in leukemia. 
These studies have shown us respectively, that immune evasion can be overcome, 
that T cells have the potential to induce the lasting regression of solid vascularized 
tumors, and that engineering of T cell responses is safe and feasible. Moreover 
childhood cancers have a range of potential targets on the cell surface (table 3) that 
are ripe for therapeutic exploitation. 
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Table 1. Representative recent or current clinical trials in pediatric patients outlining 
the range of therapeutic approaches being developed.  
 
Trial Title Description Clinical 
trials.gov ID 
Antigen-targeting antibodies   
CH14.18 1021 Antibody and IL2 After Haplo SCT in 
Children With Relapsed Neuroblastoma 
Antibody and cytokine in allogeneic 
setting 
NCT02258815 
 
Hu14.18-Interleukin-2 Fusion Protein in Treating Young 
Patients With Recurrent or Refractory Neuroblastoma 
Immunocytokine NCT00082758 
 
Monoclonal Antibody 3F8 and Sargramostim in 
Treating Patients With Neuroblastoma 
Anti-GD2 antibody (MSKCC group) 
in combination with GM-CSF 
NCT00072358 
 
Dinutuximab in Combination With Sargramostim in 
Treating Patients With Recurrent Osteosarcoma 
Anti-GD2 antibody in combination 
with GM-CSF 
NCT02484443 
 
Cytokine based therapies   
Pilot Study of Zoledronic Acid and Interleukin-2 for 
Refractory Pediatric Neuroblastoma 
Cytokine and agent to boost innate 
 lymphocytes 
NCT01404702 
 
Immune checkpoint targeting   
Pilot Study of Nivolumab in Pediatric Patients With 
Hypermutant Cancers 
PD (L)1 pathway blocking antibody 
for mutation-high gliomas 
NCT02992964 
 
A Single-Arm Study to Evaluate the Safety, Tolerability, 
Pharmacokinetics, Immunogenicity, and Preliminary 
Efficacy of MPDL3280A (Anti-PD-L1 Antibody) 
in Pediatric and Young Adult Participants With 
Solid Tumors 
PD (L)1 pathway blocking antibody 
for solid tumours 
NCT02541604 
 
Enoblituzumab (MGA271) in Children With B7-H3-
expressing Solid Tumors 
B7- H3 is member of the B7 familiy 
with homology with  PD-L1  
NCT02982941 
 
Pembrolizumab in Treating Younger Patients With 
Recurrent, Progressive, or Refractory High-Grade 
Gliomas, Diffuse Intrinsic Pontine Gliomas, or 
Hypermutated Brain Tumors 
PD (L)1 pathway blocking antibody 
for brain tumours 
NCT02359565 
 
Vaccine –based studies   
A Pilot Study of Autologous T-Cell Transplantation 
With Vaccine Driven Expansion of Anti-Tumor Effectors 
After Cytoreductive Therapy in 
Metastatic Pediatric Sarcomas 
Using ex vivo expanded autologous 
lymphocytes with a vaccine to boost 
effector cell function 
NCT00001566 
 
A Pilot Study of Tumor Cell Vaccine for High-risk 
Solid Tumor Patients Following Stem Cell 
Transplantation 
Using the setting of resetting the 
immune system following transplant 
to vaccinate agasint tumour 
antigens 
NCT00405327 
 
Dendritic Cell Vaccine Therapy With In Situ Maturation 
in Pediatric Brain Tumors 
Vaccine approach using immature 
DC 
NCT01902771 
 
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal 
Cell Carcinoma, Alveolar Soft Part Sarcoma and 
Children With Stage IV Melanoma 
Vaccine made from autologous 
tumour cells and GM-CSF 
NCT00258687 
 
Therapy to Treat Ewing's Sarcoma, 
Rhabdomyosarcoma or Neuroblastoma 
 
Using autologous tumour cells as 
vaccine 
NCT00923351 
 
Cell therapy   
Haploidentical Transplant With NK Cell Infusion for 
Pediatric Acute Leukemia and Solid Tumors 
Ex vivo expansion and infusion 
without genetic modification 
NCT00582816 
 
Genetically modified T cells   
3rd generation gd2 specific chimeric antigen receptor 
transduced autologous natural killer t-cells 
for neuroblastoma (ginakit) 
Novel approach to use CAR within 
cells with existing innate killing 
properties 
NCT02439788 
 
3rd Generation GD-2 Chimeric Antigen Receptor and 
icaspase Suicide Safety Switch, Neuroblastoma, 
GRAIN (GRAIN) 
Third generation CAR for 
neroblastoma 
NCT01822652 
 
A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-
CART) 
Second generation CAR for 
neuroblastoma 
NCT02761915 
 
A Phase I Trial of T Cells Expressing an Anti-
GD2 Chimeric Antigen Receptor in Children and Young 
Adults With GD2+ Solid Tumors 
Third generation CAR for all 
childhood cancers expressing GD2 
neroblastoma 
NCT02107963 
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Table 2. Potential combination agents to use with gene modified T cells for childhood 
solid cancers. 
 
 
Agent Mechanisms of Action Refs Suitability for combination with 1RG-CART 
Sunitinib  Reduces viability of MDSC in preclinical 
studies and clinical trials probably through 
targeting STAT3 
[54, 56, 57, 110]  Readily available and well tolerated in paediatrics 
 Clinical trial evidence of inhibition of MDSC[43] 
Chemotherapy 
Gemcitabine  
Cytotoxic/biologic agents with high degree 
of myeloid toxicity; Known to kill MSDC; 
alternative agents of  conditioning agent 
pre adoptive transfer 
[94, 95, 110]  Readily available 
 Pediatric safety data available 
 Dose for MDSC depletion not known. 
 Potential to replace cyclophosphamide 
Plerixafor Disruption of CXCR4-CXCL12 interaction 
at the surface of tumor cells 
[11, 65, 103, 105]  CXCL12 known to be expressed on neuroblastoma stromal 
cells 
 CXCR4 expression on MDSC drives their migration to 
tumor 
Celecoxib COX2 inhibitor. COX2 stimulates Arginase 
production in MDSC through stimulation by 
PG-E2 
[40, 61-67]  COX 2 redegulated in neuroblastoma 
 Preclinical data for COX2 inhibitors in neuroblastoma 
 Celecoxib will tolerated and readily available 
 Clinical trial evidence of inhibition of MDSC function 
Arginase Inhibitor 
CB1158 
Reverses the effect of tumor-induced 
arginases that create an arginine-deplete 
local and systemic microenvironment 
[50, 111]  Drug currently in phase II in adults 
 Negotiation with pharma required 
 
Sildenafil targets PDE-5 in MDSC and has been 
shown to augment antitumor immunity  
[68-70].  Readily available 
 Good safety profile in paediatrics 
 No clinical trial data of its MDSC inhibitory effect 
Ipilimumab +/- 
Nivolumab 
 
 
 
Checkpoint inhibitor antibodies that target 
the CTLA-4 and PL1 T cell inhibitory 
pathways respectively. Nivolumab will 
block interaction of PD-L1 high MDSC and 
TAMs with CAR T cells. Ipilimumab blocks 
inhibition induced by CD80/86 on tumor 
infiltrating myeloid cells and is cytotoxic for 
regulatory T cells that are induced by 
MDSC. Responses to ipilimumab correlate 
with decrease in circulating MDSC  
[101, 102, 112, 
113] 
 Anecodal use of PD1 blockade with third generation GD2-
CAR does not improve CAR expansion 
 Single agent Ipilimumab and PD1 pathway inhibitor studies 
in paediatrics have limited clinical response 
 More activity for combination therapies than single agent in 
many cancer types 
 Ipi/Nivo combination possible through BMS-otherwise 
prohibitively expensive.  
immunocytokines 
L19-IL-2 
Hu14.18-IL2 
Capable of local delivery of IL-2 to the 
tumor site 
[108, 109]  Pediatric phase I data for hu14.18-IL-2 but not for L19-IL-2  
 Neither agent available commercially 
All Trans Retinoic 
Acid 
Reduces number of monocytic MDSCs and 
diminishes the suppressive potency of 
granulocytic MDSCs 
[78-84, 114].  Readily available and well tolerated in paediatrics 
 Animal data for MDSC inhibition 
 But no human proof of concept data 
Curcumin Anti inflammatory, anti Jak2/STAT3, COX2 
inhibition 
[71-76]  Strong preclinical evidence 
 Minimal clinical proof of concept studies 
 Minimal toxicity 
 Scheduling and pharmacodynamics unknown.  
Bevacizumab Normalizes the vasculature to decrease 
tumor hypoxia, decrease pathway to 
promote MDSC, and allow greater entry of 
T cells into tumor 
[115] 
 
 Readily available but expensive 
 Good phase I data in paediatrics 
 The vascular normalization hypothesis for improved T cell 
function in humans has yet to be tested 
Withaverin Anti-tumor activitiy in many models 
Thought to function via STAT3 and 
inhibition of immune suppression in 
microenvironment 
[85, 86]  Well tolerated but needs clinical evidence of 
immunomodulatory activity in humans 
Nitroaspirin Increased the number and function of 
tumor Ag-specific T lymphocytes in vitro 
and in vivo by decreasing ARG and NOS 
activity in CD11
+ 
B lymphocytes  
[58, 110]  No previous clinical trial evaluation in adult of pediatric 
cancer patients 
Gemtuzumab Direct cytotoxicity of myeloid cells expressing 
CD33 
[88]  Safety and efficacy concerns in AML 
 No evidence that it is toxic/lytic to MDSC 
CSF-1 inhibitor Small molecules and antibodies to target 
tumor associated macrophages 
CSF-1R is expressed on MDSC 
[87]  Not evaluated in paediatrics 
 No preclinical data in neuroblastoma 
 Requires pharmaceutical collaboration 
Hyperbaric oxygen Tissue hypoxia drives MDSC  [116]  No clinical trial evidence for its effect on T cell function 
 Requires oxygen chamber which is unacceptable in phase 
I pediatric setting 
 Evidence that HBO can drive tumor growth in some cancers 
IDO inhibitor IDO is produced by MDSC and by tumor 
cells and inhibits T cells function by several 
mechanisms including depletion of 
tryptophan in microenvironment. 
[77]  No published evidence for an IDO mechanism in 
neuroblastoma 
 5-Methyl Tryptophan is the only agent tested in paediatrics 
but has limited clinical efficacy 
MEK inhibitor Trametinib Improves functionality of 
adoptively transferred T cells in Pmel 
model. MEK pathway activation in 
neuroblastoma 
[117]  Phase I data available in paediatrics and well tolerated 
 No clinical evidence of its effect on MDSC function or 
activity in neuroblastoma 
 Requires pharmaceutical collaboration 
5-FU Myelotoxic chemotherapy  [96, 97]  No clinical evidence of its inhibitory function on MDSC 
 Contradictory data; potential for stimulation of MDSC 
TGF-beta inhibition 
Fresolimab 
Galunisertib 
TGF-β is a fundamental pathway of 
suppression by MDSC.  
  Development and proof of efficacy of TGF-β inhibitors has 
been disappointing despite many years of effort 
Lenolidamide and 
related inhibitors 
Inhibitory effects on range of regulatory 
immune cells 
 Competing with other studies in pediatrics 
Little direct evidence for role in neuroblastoma 
Requires pharmaceutical collaboration 
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Table 3. Examples of potential target antigens for pediatric cancers. Direct 
targeting with antibodies or CAR T cells is possible with molecules naturally resident 
on the cell surface and absent from most normal tissues. Tumor specific antigens arise 
as a result of a characteristic mutation. For such an antigen to be targeted by T cells 
the mutated amino acids must have the appropriate affinity for self MHC to be 
presented as a peptide fragment; for example the peptides spanning a chromosomal 
translocation breakpoint. Non membrane bound tumor associated antigens also 
require presentation on the cell membrane with MHC and are non mutated (self) 
peptides but distinguishable by the immune system from non-tumor tissues by virtue 
of low level expression on normal tissues. For detailed reference list see [118, 119]. 
 
Antigen Cancer 
Directly Targetable cell surface molecules 
GD2 Neuroblastoma, sarcomas 
ALK Neuroblastoma, IMT, rhabdomyosarcoma 
FGFR4 Rhabdomyosarcoma 
B7H3 Pontine glioma, neuroblastoma 
IGF1R Ewing sarcoma, RMS 
EGFR Medulloblastoma, glioma, sarcoma 
STEAP-1 Ewing sarcoma 
Fetal Acetylcholine 
receptor 
Ewing sarcoma, rhabdomyosarcoma 
PDGFR High grade glioma 
Tumor-Specific Antigens 
PAX3/7-FOXO Alveolar rhabdomyosarcoma 
Histone H3 mutation Midline high grade gliomas 
Ewings translocations Ewing family sarcomas 
EWS-WT1 fusion Desmoplastic small round cell tumor 
Non-membrane bound Tumor associated antigens  
WT1 Wilms’ rhabdomyosarcoma 
NY-ESO Synovial sarcoma 
PRAME Neuroblastoma, pontine glioma, Ewing, 
osteosarcoma, medulloblastoma 
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